Literature DB >> 28339163

Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.

Sasinya N Scott1, Irina Ostrovnaya2, Caroline M Lin1, Nancy Bouvier1, Bernard H Bochner3, Gopakumar Iyer4, David Solit4, Michael F Berger1,5, Oscar Lin1.   

Abstract

BACKGROUND: Biopsies from patients with high-risk (HR) non-muscle-invasive urothelial carcinoma (NMIUC), especially flat urothelial carcinoma in situ, frequently contain scant diagnostic material or denuded mucosa only, and this precludes further extensive genomic analysis. This study evaluated the use of next-generation sequencing (NGS) analysis of urine cytology material from patients with HR NMIUC in an attempt to identify genetic alterations that might correlate with clinical features and responses to bacille Calmette-Guérin (BCG) treatment.
METHODS: Forty-one cytology slides from patients with HR NMIUC treated with intravesical BCG were selected for this study. Histological confirmation was available for all cases. The specimens were subjected to NGS analysis with a customized targeted exome capture assay composed of 341 genes.
RESULTS: In this cohort, genomic alterations were successfully identified in all cytology samples. Mutations were detected down to a 2% allele frequency and chromosomal rearrangements including copy number alterations and gene fusions were identified. The most frequently altered genes included telomerase reverse transcriptase (TERT), tumor protein 53 (TP53), Erb-B2 receptor tyrosine kinase 2 (ERBB2), and chromatin remodeling genes such as lysine demethylase 6A (KDM6A) and AT-rich interaction domain 1A (ARID1A). For patients with matched tumor tissue, cytology specimens revealed all mutations detected in tissue as well as additional mutations, and this suggested that urine might more effectively capture the full genetic heterogeneity of disease than an individual cystectomy. Alterations in multiple genes correlated with clinical and histopathological features, including responses to BCG treatment, flat architecture versus papillary architecture, and smoking history.
CONCLUSIONS: Urine specimens can replace tissue as a substrate for NGS analysis of HR NMIUC. Several genomic alterations identified in urine specimens might be associated with histological features and clinical characteristics. Cancer Cytopathol 2017;125:416-26.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  bacille Calmette-Guérin (BCG); bladder cancer; next-generation sequencing; urine cytology

Mesh:

Substances:

Year:  2017        PMID: 28339163      PMCID: PMC5477237          DOI: 10.1002/cncy.21847

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  53 in total

Review 1.  Diagnosis and staging of bladder cancer.

Authors:  Maxine Sun; Quoc-Dien Trinh
Journal:  Hematol Oncol Clin North Am       Date:  2014-11-06       Impact factor: 3.722

2.  TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.

Authors:  Isaac Kinde; Enrico Munari; Sheila F Faraj; Ralph H Hruban; Mark Schoenberg; Trinity Bivalacqua; Mohamad Allaf; Simeon Springer; Yuxuan Wang; Luis A Diaz; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; George J Netto
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

3.  PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

Authors:  Elena López-Knowles; Silvia Hernández; Núria Malats; Manolis Kogevinas; Josep Lloreta; Alfredo Carrato; Adonina Tardón; Consol Serra; Francisco X Real
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

4.  Best practice in the treatment of nonmuscle invasive bladder cancer.

Authors:  Anastasios Anastasiadis; Theo M de Reijke
Journal:  Ther Adv Urol       Date:  2012-02

5.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.

Authors:  C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

6.  ATM polymorphisms and risk of lung cancer among never smokers.

Authors:  Yen-Li Lo; Chin-Fu Hsiao; Yuh-Shan Jou; Gee-Chen Chang; Ying-Huang Tsai; Wu-Chou Su; Yuh-Min Chen; Ming-Shyan Huang; Hui-Ling Chen; Pan-Chyr Yang; Chien-Jen Chen; Chao A Hsiung
Journal:  Lung Cancer       Date:  2009-12-11       Impact factor: 5.705

7.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.

Authors:  Yves Fradet; H Barton Grossman; Leonard Gomella; Seth Lerner; Michael Cookson; David Albala; Michael J Droller
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

Review 8.  Molecular genetics of bladder cancer: an update.

Authors:  T Díaz De Ståhl; U Segersten; P U Malmström
Journal:  Minerva Urol Nefrol       Date:  2008-12       Impact factor: 3.720

Review 9.  Genetic alterations in urothelial bladder carcinoma: an updated review.

Authors:  Paulette Mhawech-Fauceglia; Richard T Cheney; Juerg Schwaller
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  9 in total

Review 1.  Advances in bladder cancer biology and therapy.

Authors:  Linda Tran; Jin-Fen Xiao; Neeraj Agarwal; Jason E Duex; Dan Theodorescu
Journal:  Nat Rev Cancer       Date:  2020-12-02       Impact factor: 69.800

Review 2.  Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction.

Authors:  Karl H Pang; Francesco Esperto; Aidan P Noon
Journal:  Transl Androl Urol       Date:  2017-12

Review 3.  Unmasking molecular profiles of bladder cancer.

Authors:  Xuan-Mei Piao; Young Joon Byun; Wun-Jae Kim; Jayoung Kim
Journal:  Investig Clin Urol       Date:  2018-02-01

4.  Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.

Authors:  Lingyun Liu; Jinghai Hu; Yu Wang; Tao Sun; Xiang Zhou; Xinyuan Li; Fuzhe Ma
Journal:  Aging (Albany NY)       Date:  2020-06-22       Impact factor: 5.682

5.  ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?

Authors:  Stefan Garczyk; Ursula Schneider; Isabella Lurje; Katharina Becker; Thomas A Vögeli; Nadine T Gaisa; Ruth Knüchel
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

Review 6.  Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.

Authors:  Dongkui Song; Thomas Powles; Lei Shi; Lirong Zhang; Molly A Ingersoll; Yong-Jie Lu
Journal:  J Pathol       Date:  2019-06-24       Impact factor: 7.996

Review 7.  Molecular profiling for precision cancer therapies.

Authors:  Eoghan R Malone; Marc Oliva; Peter J B Sabatini; Tracy L Stockley; Lillian L Siu
Journal:  Genome Med       Date:  2020-01-14       Impact factor: 11.117

Review 8.  Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?

Authors:  Nada Humayun-Zakaria; Douglas G Ward; Roland Arnold; Richard T Bryan
Journal:  Transl Androl Urol       Date:  2021-06

9.  Massively parallel sequencing of urinary DNA-the dawn of non-invasive bladder cancer detection and surveillance?

Authors:  Douglas G Ward; Richard T Bryan
Journal:  Transl Cancer Res       Date:  2019-03       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.